Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
86.16
+0.07 (0.08%)
Aug 1, 2025, 4:00 PM - Market closed
Smartsheet Revenue
Glaukos had revenue of $124.12M in the quarter ending June 30, 2025, with 29.71% growth. This brings the company's revenue in the last twelve months to $432.95M, up 26.70% year-over-year. In the year 2024, Glaukos had annual revenue of $383.48M with 21.85% growth.
Revenue (ttm)
$432.95M
Revenue Growth
+26.70%
P/S Ratio
11.17
Revenue / Employee
$435,129
Employees
995
Market Cap
4.93B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GKOS News
- 1 day ago - Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Glaukos Announces Second Quarter 2025 Financial Results - Business Wire
- 23 days ago - Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30 - Business Wire
- 5 weeks ago - Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies - Business Wire
- 5 weeks ago - Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell - Business Wire
- 2 months ago - Glaukos Announces Participation in Upcoming Investor Conferences - Business Wire
- 3 months ago - Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Glaukos Announces First Quarter 2025 Financial Results - Business Wire